ERGO Ergomed Plc

TIDMERGO

RNS Number : 5095G

Ergomed plc

16 November 2022

PRESS RELEASE

Exercise of Share Options and Total Voting Rights

Guildford, UK - 16 November 2022: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company") announces that, following an exercise of share options, application has been made to AIM for the admission of 40,000 new ordinary shares of 1p each in the capital of the Company (the "New Ordinary Shares").

Admission to trading on AIM of the New Ordinary Shares ("Admission") is expected to occur on 21 November 2022. Following Admission, the New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares.

Following Admission, the total number of ordinary shares with voting rights in issue will be 50,128,805. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

ENDS

Enquiries:

Ergomed plc Tel: +44 (0) 1483 402 975

Dr Miroslav Reljanović (Executive Chairman)

Richard Barfield (Chief Financial Officer)

Keith Byrne (Senior Vice-President, Capital Markets & Strategy)

Numis Tel: +44 (0) 20 7260 1000

   Freddie Barnfield /   Euan Brown   (Nominated Adviser) 

James Black (Broker)

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel / Dr Christopher Golden

   Consilium Strategic Communications                                  Tel: +44 (0) 20 3709 5700 

Chris Gardner / Matthew Neal ergomed@consilium-comms.com

Angela Gray

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information,

visit:   http://ergomedplc.com . 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCBABFTMTIBBMT

(END) Dow Jones Newswires

November 16, 2022 02:00 ET (07:00 GMT)

Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024